Loading...
XTAEREKA
Market cap41mUSD
Dec 24, Last price  
1,312.00ILS
1D
-2.67%
1Q
0.77%
Jan 2017
-37.13%
Name

Rekah Pharmaceutical Industry Ltd

Chart & Performance

D1W1MN
XTAE:REKA chart
P/E
—
P/S
46.56
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.89%
Rev. gr., 5y
9.13%
Revenues
322m
+10.01%
269,998,000270,032,000216,372,000262,429,000218,385,000208,184,000207,829,000196,499,000265,473,000263,950,000292,394,000321,663,000
Net income
-7m
L+238.23%
7,403,0008,320,000-501,000-4,414,000-11,000,000-22,480,0007,027,0002,755,00010,797,0006,624,000-2,043,000-6,910,000
CFO
28m
-27.31%
14,182,00011,706,0001,330,0005,806,00022,825,00023,797,00017,284,00033,913,00011,283,00021,169,00039,002,00028,350,000
Dividend
Apr 06, 202286.776 ILS/sh
Earnings
May 09, 2025

Profile

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields. Rekah Pharmaceutical Industry Ltd. was founded in 1941 and is based in Holon, Israel.
URL
https://www.rekah.co.il/
IPO date
Dec 14, 1995
Employees
399
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
321,663
10.01%
292,394
10.78%
263,950
-0.57%
Cost of revenue
316,280
229,537
210,916
Unusual Expense (Income)
NOPBT
5,383
62,857
53,034
NOPBT Margin
1.67%
21.50%
20.09%
Operating Taxes
138
2,400
1,096
Tax Rate
2.56%
3.82%
2.07%
NOPAT
5,245
60,457
51,938
Net income
(6,910)
238.23%
(2,043)
-130.84%
6,624
-38.65%
Dividends
(10,000)
Dividend yield
5.69%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
30,055
25,160
24,000
Long-term debt
194,499
172,352
187,453
Deferred revenue
9,218
Other long-term liabilities
36,505
15,346
11,213
Net debt
204,034
177,224
192,811
Cash flow
Cash from operating activities
28,350
39,002
21,169
CAPEX
(11,489)
(7,482)
(13,994)
Cash from investing activities
(21,499)
(13,449)
(35,902)
Cash from financing activities
(7,783)
(24,356)
(2,777)
FCF
4,649
93,634
42,388
Balance
Cash
19,349
20,288
18,642
Long term investments
1,171
Excess cash
4,437
5,668
5,444
Stockholders' equity
29,478
35,973
46,958
Invested Capital
366,553
325,378
353,614
ROIC
1.52%
17.81%
15.49%
ROCE
1.45%
18.83%
14.64%
EV
Common stock shares outstanding
11,415
11,415
11,415
Price
14.78
-3.96%
15.39
-33.89%
23.28
-13.13%
Market cap
168,708
-3.96%
175,671
-33.89%
265,733
-13.13%
EV
372,790
352,945
458,596
EBITDA
35,220
90,338
75,892
EV/EBITDA
10.58
3.91
6.04
Interest
5,646
5,634
Interest/NOPBT
8.98%
10.62%